IEEE Spectrum on MSN
Why the most accurate glucose monitors are failing some users
In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings.
Stelo by Dexcom is a wearable glucose biosensor that brings continuous glucose monitoring into the consumer wellness space, ...
Abstract: Convolutional neural networks (CNNs) and Transformers have made impressive progress in the field of remote sensing change detection (CD). However, both architectures have inherent ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
The G7 15 Day CGM in use. [Image courtesy of Dexcom] Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next month. The San ...
Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. The company said its Smart Basal ...
Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...
The Smart Basal offering with the G7 CGM. [Images courtesy of Dexcom] Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback